BioLife Solutions is poised to benefit from the booming cell and gene therapy sector. Read more to see my investment strategy ...
Clorox (NYSE:CLX – Get Free Report) had its target price cut by investment analysts at Wells Fargo & Company from $161.00 to ...
MarketBeat on MSN2d
Big Buybacks: 3 Large Caps Exceed 5% Repurchase PowerMultiple large-cap stocks have recently announced substantial share buyback authorizations. With these announcements, three ...
Q4 2024 Earnings Call Transcript April 1, 2025 Operator: All sites on hold. We do appreciate your patience in holding and ask ...
Emergent BioSolutions (NYSE:EBS – Get Free Report) declared that its board has approved a share repurchase plan on Monday, March 31st, RTT News reports. The company plans to buyback $50.00 million in ...
More than 60% of operating profit is derived from resilient categories with low private label penetration and strong brand loyalty, where Nestle exhibits evident pricing power.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback